Intranasal zavegepant is effective and well tolerated for the acute treatment of migraine: A phase 2/3 dose-ranging clinical trial

被引：0
|
作者：
Croop, R. [1 ]
Madonia, J. [1 ]
Conway, C. M. [1 ]
Thiry, A. C. [1 ]
Forshaw, M. [1 ]
Murphy, A. [1 ]
Jensen, C. M. [1 ]
Dubowchik, G. M. [1 ]
Coric, V [1 ]
Lipton, R. B. [2 ]
机构：
[1] Biohaven Pharmaceut Inc, New Haven, CT USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
HEADACHE | 2021年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IOR-11
引用
收藏
页码：104 / 105
页数：2
相关论文
共 50 条
  • [1] Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical Trial
    Lipton, R. B.
    Madonia, J.
    Conway, C. M.
    Thiry, A.
    Forshaw, M.
    Murphy, A.
    Jensen, C. M.
    Dubowchik, G.
    Coric, V.
    Croop, R.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 147 - 147
  • [2] Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical Trial
    Lipton, R. B.
    Madonia, J.
    Conway, C. M.
    Thiry, A.
    Forshaw, M.
    Murphy, A.
    Jensen, C. M.
    Dubowchik, G.
    Coric, V.
    Croop, R.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 99 - 99
  • [3] Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical trial
    Croop, Robert
    Madonia, Jennifer
    Conway, Charles
    Thiry, Alexandra
    Forshaw, Micaela
    Murphy, Abigail
    Jensen, Christopher
    Dubowchik, Gene
    Coric, Vlad
    Lipton, Richard
    [J]. NEUROLOGY, 2021, 96 (15)
  • [4] Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial
    Croop, Robert
    Madonia, Jennifer
    Stock, David A.
    Thiry, Alexandra
    Forshaw, Micaela
    Murphy, Abigail
    Coric, Vladimir
    Lipton, Richard B.
    [J]. HEADACHE, 2022, 62 (09): : 1153 - 1163
  • [5] Naratriptan is effective and well tolerated in the acute treatment of migraine
    Tfelt-Hansen, P
    Goadsby, PJ
    [J]. NEUROLOGY, 1999, 52 (06) : 1300 - 1300
  • [6] Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study
    Dahlof, C
    Hogenhuis, L
    Olesen, J
    Petit, H
    Ribbat, J
    Schoenen, J
    Boswell, D
    Fuseau, E
    Hassani, H
    Winter, P
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (05) : 469 - 477
  • [7] Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine
    Peikert, A
    Becker, WJ
    Ashford, EA
    Dahlof, C
    Hassani, H
    Salonen, RJ
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 (01) : 43 - 49
  • [8] Efficacy of naratriptan tablets in the acute treatment of migraine:: A dose-ranging study
    Havanka, H
    Dahlöf, C
    Pop, PHM
    Diener, HC
    Winter, P
    Whitehouse, H
    Hassani, H
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (08) : 970 - 980
  • [9] Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well tolerated: Results from a phase 2 dose-ranging clinical trial
    Thuren, T
    Longcore, A
    Powell, C
    Strand, J
    Durham, K
    Shear, C
    [J]. CIRCULATION, 2005, 112 (17) : U235 - U235
  • [10] Zolmitriptan is effective and well tolerated in both acute and prophylactic treatment of menstrual migraine
    Tuchman, Michael
    Emeribe, Ugochinyere
    [J]. NEUROLOGY, 2007, 68 (12) : A260 - A261
12345